C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

Head and Neck

Volumn 27, Issue 10, 2005, Pages 883-892

  Olsen, Randall J ^a   Lydiatt, William M ^b   Koepsell, Scott A ^c   Lydiatt, Daniel ^b   Johansson, Sonny L ^c   Naumann, Sabine ^c   Bridge, Julia A ^c   Neff, James R ^c   Hinrichs, Steven H ^c   Tarantolo, Stefano R ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Methodist Cancer Center   (United States)

Author keywords

C erb B2; HER2 neu; Synovial sarcoma; Trastuzumab

Indexed keywords

ALPHA ACTIN; CYTOKERATIN 6; DESMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; NEURON SPECIFIC ENOLASE; TRASTUZUMAB; VIMENTIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SYNOVIAL SARCOMA; THORAX WALL; WESTERN BLOTTING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHILD; FEMALE; GENES, ERBB-2; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SARCOMA, SYNOVIAL;

EID: 25844472319     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20267     Document Type: Article

References (52)

1. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78.
2. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A 1988;85:5394-5398.
3. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230:1132-1139.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
5. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-264.
6. Menard S. HER2 overexpression in various tumor types. Proceedings of the HER2 State-of-the-Art Conference, Montreux, Switzerland, 1999.
7. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-1032.
8. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol 2001;28:3-11.
9. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-898.
10. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-3266.
11. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159-7163.
12. Andrulis IL, Bull SB, Blackstein ME, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349.
13. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with their prognostic markers. J Clin Oncol 1998;16:462-469.
14. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172.
15. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
16. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
17. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
18. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
19. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her2/neu, protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-381.
20. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
21. Bosilevac JM, Olsen RJ, Bridge JA, Hinrichs SH. Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. J Biol Chem 1999;274:34811-34818.
22. Olsen RJ, Hinrichs SH. Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins. Oncogene 2001;20:1756-1764.
23. Olsen RJ, Tarantolo SR, Hinrichs SH. Molecular approaches to sarcoma therapy. Sarcoma 2002;6:27-42.
24. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop 2001;382:59-65.
25. Li N, Shen LH, Zhu QF. Overexpression of c-erbB-2 proto-oncogene product in chondrosarcomas. Zhonghua Bing Li Xue Za Zhi 1994;23:37-39.
26. Mark HF, Brown S, Sun CL, Samy M, Afify A. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 1998;66:59-63.
27. Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001; 61:3394-3398.
28. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-381.
29. Allander SV, Illei PB, Chen Y, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161:1587-1595.
30. Bae CD, Park SE, Seong YS, Kimm SW, Park JB, Park JB. The mechanism of c-erb-B2 gene product increase in stomach cancer cell lines. J Korean Med Sci 1993;8:153-159.
31. Bae CD, Juhnn YS, Park JB. Post-transcriptional control of c-erb-B2 overexpression in stomach cancer cells. Exp Mol Med 2001;33:15-19.
32. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:14-21.
33. Tubbs RR, Stoler MH. The quality of Her2/neu predictive immunohistochemistry: something FISHy? Mod Pathol 2000;13:1-3.
34. Hollywood DP, Hurst HC. Targeting gene transcription: a new strategy to down regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer 1995;71:753-757.
35. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogenec-erbB-2 in mammary tumor lines. EMBO J 1995;12:2369-2375.
36. Child SJ, Miller MK, Geballe AP. Translational control by an upstream open reading frame in the HER-2/neu transcript. J Biol Chem 1999;274:24335- 24341.
37. Kawauchi S, Fukuda T, Oda Y, et al. Prognostic significance of apoptosis in synovial sarcoma. Mod Pathol 2000; 13:755-765.
38. Kawauchi S, Goto Y, Ihara K, et al. Survival analysis with p27 expression and apoptosis appears to estimate the prognosis of patients with synovial sarcoma more accurately. Cancer 2002;94:2712-2718.
39. George E, Niehans GA, Swanson PE, Strickler JG, Singleton TP. Overexpression of the c-erbB-2 oncogene in sarcomas and small round cell tumors of childhood: an immunohistochemical investigation. Arch Pathol Lab Med 1992;116:1033-1035.
40. Mermimsky O, Issakov J, Schwartz I, et al. Lack of ErbB-2 oncogene product overexpression in soft tissue sarcomas. Acta Oncol 2002;41:366-368.
41. Nuciforo PG, Pellegrini C, Fasani R, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 2003;34:639-645.
42. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963-970.
43. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer 1999;85:2596-2607.
44. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-160.
45. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Can Res 2002;62:135-140.
46. Brodsky JT, Burt ME, Hajdu SI, Casper ES, Brennan MF. Tendosynovial sarcoma: clinicopathologic features, treatment, and prognosis. Cancer 1992;70:484-489.
47. Pai S, Chinoy RF, Pradhan SA, D'Cruz AK, Kane SV, Yadav JN. Head and neck synovial sarcomas. J Surg Oncol 1993;54:82-86.
48. Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a follow-up study of 24 cases. Cancer 1975;35:1243-1253.
49. Amble FR, Olsen KD, Nascimento AG, Foote RL. Head and neck synovial cell sarcoma. Otolaryngol Head Neck Surg 1992;107:631-637.
50. Weiss SW, Goldblum JR, Franz M. Enzinger and Weiss's soft tissue tumors, 3rd ed. St Louis: Mosby-Year Book, Inc; 2001.
51. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
52. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-1307.